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Abstract
Background: Patients with Inflammatory Bowel Disease (IBD) also suffer from a wide range of additional disorders,
which may be caused by the disease, the side effect of the medication, or a lack of physical activity (PA). This
results in reduced physical and psychological wellbeing. However, as known from other chronic diseases exercise
could be utilized as supportive therapy for IBD patients. Main goals of this article are (a) collecting data of the
effects structured physical activity interventions have on validated clinical parameters of IBD and health related
symptoms, (b) developing activity recommendations for this clientele.
Methods: A scoping review was conducted, searching for relevant articles published until May 2018, which
investigated the effects of structured exercise interventions in IBD patients. The heterogeneity of the outcomes and
the interventions did not support a quantitative synthesis thus, a qualitative discussion of the studies is provided.
Results: After reviewing 353 records, 13 eligible articles were identified. Five studies investigated aerobic exercise,
three studies resistance exercise, three studies mind-body therapies and two studies yoga. The quality of the
studies is mixed, and the duration is rather short for exercise interventions. Only few studies assessed validated IBD
activity markers or inflammatory biomarkers. Nevertheless, the patients showed an increase in fitness, bone mineral
density (BMD), quality of life and a decrease of IBD induced stress and anxiety. No severe adversial events were
reported.
Conclusion: Even though the evidence is limited the application of exercise interventions in IBD patients can be
assumed to be safe and beneficial for the patients‘ overall-health, and IBD specific physical and psychosocial
symptoms. But there is still a high demand for more thoroughly conducted studies, focussing on important clinical
outcome parameters.
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Background
Inflammatory Bowel Disease (IBD) is a chronic intestinal
inflammatory illness, characterized by periods of remis-
sions and relapses [1, 2]. The two main types of IBD are
Crohn’s disease (CD) and ulcerative colitis (UC). Whereas
UC is restricted to the large intestines and the rectum,
specifically the mucosa and superficial submucosa, CD is
transmural and can affect any part of the gastrointestinal
tract [3, 4]. Until now the highest relative prevalence of
IBD has been reported in European countries (UC, 505
per 100.000 persons in Norway; CD, 322 per 100.000 per-
sons in Germany) in addition it appears be rising world-
wide. While most of the industrialized nations display
stable incidence rates of IBD, an increasing number of
new cases can be observed in emerging countries [5].
There is still a lack of knowledge in regards to the
pathophysiology and the etiology of IBD, meaning, its
origin seems to be multifactorial and influenced by an
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: keckert@ist-hochschule.de
1IST University of Applied Sciences, Health Management and Public Health,
Düsseldorf, Germany
Full list of author information is available at the end of the article
Eckert et al. BMC Gastroenterology          (2019) 19:115 
https://doi.org/10.1186/s12876-019-1034-9
abnormal immune response to gut microbes in a genet-
ically predisposed person [6, 7]. Both diseases show
symptoms like diarrhea, abdominal cramps and pain,
rectal bleeding and weight loss [8]. These symptoms are
often accompanied by further extraintestinal health
problems [9], such as reduced BMD and osteoporosis
[10–12] fatigue [13, 14], or depressive symptoms [15], a
decrease in physical fitness [16–18], and an impaired
overall health related quality of life (HrQoL) [12, 19, 20]
that are caused by the disease, as side effects of the med-
ical treatments [21, 22] and a lack of PA [23, 24].
Medical treatment is often necessary throughout the
patient’s lifetime. Current treatments for IBD consist
of medications like 5-aminosalicylic acid compounds,
corticosteroids, immunosuppressants and biologics.
The main cost driver is Anti-Tumor Necrosis Factor
alpha (Anti-TNF α) therapy, which accounts for 64%
of the total costs in CD and 31% of the total costs in
UC [25]. Studies have shown that the total annual
direct costs of patients with IBD (i.e. medication,
diagnostics, physicians and other healthcare services)
range from $ 11 to $ 28 billion in the United States
[26] and from 4.6 € to 5.6 billion € in Europe [27].
This data implicates that IBD represents a challenge
for health care systems globally. The main goal in the
treatment of IBD is to reduce the quantity and the
quality of the inflammation, ideally resulting in a clin-
ical remission. Disease activity is quantified via three
classes of indicators: clinical symptoms, inflammatory
markers and HrQoL [28].
Since there is no cure for IBD yet, currently avail-
able drugs can only tackle its symptoms by inhibiting
inflammation and delaying relapses. Despite their effi-
ciency to relief symptoms, undesirable side effects are
common [21, 22]. Therefore, many patients look for
supportive and adjunctive therapies. PA has proven to
be a factor in helping other chronic conditions, thus,
it could be a feasible approach for IBD patients [29].
However, not enough is known about the impact of
structured PA interventions on the clinical course of
IBD or side effects associated with the disease and its
treatments [30]. Hence, these are the main goals of
this paper:
a) Collecting data and giving evidence about the
effects of structured physical exercise interventions
on inflammatory biomarkers, clinical activity
metrics and HrQoL as directly with the disease
associated primary outcomes, and on physical and
psychosocial functions (e.g. muscle performance,
BMD, cardiorespiratory fitness, fatigue) as
secondary outcomes.
b) Developing PA recommendations, which are
specific for IBD patients.
Methods
Search strategy
In May 2018 a literature search was conducted using the
databases of PubMed, Cinhal and Web of Science for
relevant abstracts and articles on IBD and PA interven-
tions. The search terms included: exercise, physical
activity, PA, motor activity, resistance training, strength
training, endurance training, aerobic, sport for the
semantic space of exercise. These terms were paired
with inflammatory bowel disease, IBD, Crohn’s disease,
CD, ulcerative colitis, UC (using AND as operator). By
screening Google Scholar and the reference lists of the
included studies, overlooked studies were added. All
identified titles and abstracts were assessed for eligibility
by two reviewers independently (KE and MK).
Study selection
The following criteria determined which references were
included: Only adults (≥18 years) diagnosed either with
CD or UC. Only full-text articles written in English were
selected. Only longitudinal study designs with PA inter-
ventions were included. Studies were not limited with
regards to type of PA. All publication years were included
in the search. Studies on Irritable Bowel Syndrome were
excluded.
Data extraction
Included full texts were assessed by KE and GH inde-
pendently. The heterogeneity of the conducted interven-
tions, the inconsistency in outcome measures and the
complex nature of IBD (phenotype, location, disease ac-
tivity, medication and disease related symptoms) made a
meta-analytical synthesis of the outcomes implausible,
thus a qualitative approach was preferred to present the
current evidence. All eligible studies were classified ac-
cording to 2011 Oxford Centre for Evidence-Based
Medicine (OCEBM) levels of evidence (first column:
Does this intervention help?) [31]. The review was struc-
tured according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (the PRISMA
statement) [32].
Results
A total of n = 353 articles were identified. After exclud-
ing duplicates and scanning titles as well as abstracts,
n = 45 articles were retrieved and examined. Another
n = 6 articles were added after scanning the references of
chosen articles. These n = 51 articles were eligible for full
text screening, resulting in further exclusion of n = 41
articles. Although two abstracts and one letter to the
editor were excluded after title and abstract screening,
we included them after all due to their relevance. Thus,
13 articles were used for the qualitative analysis (Fig. 1).
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Reasons for the exclusion of articles are presented in
Table 1.
Characteristics of the studies
Thirteen studies were included in this review. Seven
studies were randomized controlled trials (RCT) [7, 30,
33–37] and six studies used a quasi-experimental design
[38–43].
Selected studies were conducted between the years
1999 and 2017, with n = 6 published within the last 4
years. The sample sizes vary from 6 to 107 subjects. Five
of the studies included patients with CD only two inves-
tigated patients with UC and six studies incorporated
both diseases. All study participants were either in
remission or had a mild to moderate disease activity at
the time of intervention. With regards to methodological
limitations, the study results are presented descriptively
in accordance with their primary results. Statistical pa-
rameters are listed if they were provided. (Table 2).
Findings by type of exercise intervention
Cardiovascular training
Five studies reported the effects of a cardiovascular
training on diverse health outcomes. D’Inca and col-
leagues found neither statistically significant changes in
the assessed gastrointestinal health parameters nor sig-
nificant changes in disease activity after 1 hour of cycle
ergometer exercise [38]. On the other hand, Loudon et
al. [39] and Ng et al. [30] observed positive effects on
stress parameters (IBD Stress Index) p < .001 [39] and
p < .05 [30]), HrQoL (IBD Questionnaire (IBDQ) p = .01
[39] and p < .05 [30]) and cardiorespiratory fitness
(VO2max p < .01 [39]) in people with CD, involving a
walking intervention taking place once a week for 3
months. A supervised outdoor running program, three
times a week for 10 weeks, resulted in significant im-
provements in the social dimension of HrQoL (IBDQ
social dimension p = .03) but showed no changes in dis-
ease activity (Crohn’s Disease Activity Index (CDAI)
Fig. 1 Flow diagram of literature search and study selection
Table 1 Reasons for exclusion of full-text articles
Reason for exclusion Number of articles excluded
No PA intervention n=29
No IBD patients n=5
Study protocol n=1
Use of same study sample n=2
Reviews / no Interventions n=4
Total number of articles excluded after
full text screening
n=41
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p = .81; Rachmilewitz Index (RI) p = .88) or laboratory
parameters (Leucocyte count (Lc) p = .39, C-reactive
protein (CRP) p = .88, fecal calprotectin (FCP) p = .90)
[36]. Hassid et al. examined the effects of different types
of high voluminous sport activities (marathon, half-
marathon, long bicycle rides and triathlon) on disease
activity (Harvey and Bradshaw Index (HBI); Simple Clin-
ical Colitis Activity Index (SCCAI)) in 17 mixed IBD pa-
tients. As result, no significant changes or harmful
effects were discovered instantly and a week after the ex-
ercise [43].
Strength training
In three studies, the patients participated strength train-
ing, with two supervised interventions were executed on
weightlifting machines [40, 42]. With only one study
assessing a disease activity index [40]. Candow and col-
leagues chose a 12-week intervention on 12 different
training machines with constant intensity and number of
repetitions [40]. The participants in De Souza Tajiris et
al. study performed an isolated, progressive training in-
volving only the quadriceps muscle [42]. Both found a
significant increase in muscle strength (p < .05 [40],
p < .001 [42]). Nevertheless, the progressive training
protocol leads to a significant improvement in patients’
HrQoL (IBDQ p < .001 [42]), but failed to decrease the
disease activity (HBI) significantly [40]. In one study, a
home- and floor-based low impact dynamic resistance
training was conducted. The intervention lasted for over
1 year and had improvements in BMD as primary out-
come. Fully compliant patients showed a significant in-
crease in BMD for the trochanter major (p = .02). All
other assessed anatomical structures showed no statisti-
cally significant increase in BMD [33].
Yoga
Cramer et al. randomly assigned 77 UC patients to ei-
ther a 12-weeks lasting traditional Hatha yoga group or
an inactive control group. Participants of the yoga group
showed significantly higher HrQoL scores (IBDQ
p = .02) and lower disease activity (RI p = .03) 24 weeks
after the intervention [37]. Sharma et al. carried out a
supervised yoga intervention over the course of 8 weeks
with patients in remission. While patients with UC
showed slightly improved anxiety scores (STAI: State
(p = .01) and Trait (p = .001) anxiety levels) and fewer
arthralgia (p < .05), patients with CD displayed no
changes. Also no impact on cardiovascular autonomic
functions or immune markers (Lc, Serum eosinophilic
cationic protein (ECP)) was observed [7].
Lifestyle intervention – mixed methods
In three studies various mind-body therapies were con-
ducted, including e.g. yoga, meditation, stress management,
nutrition, relaxation techniques, education about the
disease and cognitive behavioral techniques. Gupta et
al. found no effects on anxiety levels, disease activity or
inflammatory markers while Gerbarg and colleagues
detected significant improvements in CRP for the EG
(p = .01) but not for the CG (p = .39) [36, 41]. In a
structured and supervised mind-body therapy over a
10-week period (6 h on 1 day per week), higher HrQoL
scores for the EG were observed (SF-36 psychosocial
health sum p < .05 and IBDQ p < .01), but no effects on
disease activity (RI) or neuroendocrine and cellular im-
mune measures (Lc,TNF α) [34].
Discussion
The current review investigated the effects of structured
PA interventions on inflammatory biomarkers, clinical
activity indices and HrQoL as directly with the disease
associated primary outcomes and of physical and psy-
chosocial functions in patients as secondary outcomes. It
follows a presentation of the biological, physical and psy-
chosocial effects. Additionally, the known effects and
mechanisms of exercise in other clinical populations [29,
44] will be displayed and their potential for IBD patients
discussed.
Biologic rationale for benefits of PA interventions in IBDs
a) Inflammatory biomarkers
The conducted exercise trials report only minor changes
in laboratory markers [7, 34, 36, 37]. Three of the in-
cluded studies investigated the effects of exercise on in-
flammatory biomarkers like FCP, CRP, Lc and TNF α,
with merely one study showing a significant reduction in
CRP [36]. Despite the importance of TNF α in IBD, only
one study explored this parameter; however, no signifi-
cant effect on the TNF α basal levels were observed
within the treatment group, that conducted mind-body
therapy [34]. To the best of our knowledge, only one
additional study has investigated the relationship of PA
and inflammation in IBD patients [54]. Plöger et al. re-
ported a positive association of exercise and increased
levels of Interleukin 6 (IL-6) in children with IBD. How-
ever this study was not included in this review, since it
is limited to studies conducted in adults.
The anti-inflammatory effect of PA is well investigated
in Type 2 Diabetes and Cardiovascular diseases [45]. It
can be attributed to the release of cytokines, such as IL-
6, which affects the systemic inflammation via crosstalk
on TNF α [46, 47]. Observations of anti-inflammatory
pathways were made in murine models and have also
been confirmed in exercise studies with humans, involv-
ing strength training [48] and strenuous aerobic exercise
[49]. Even though the evidence provides a framework for
similar effects in IBD patients, it is not possible to draw
clear conclusions from the analyzed studies. However,
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the evidence with regards to the beneficial effects of
moderate PA on the immune system seems promising
[55, 56]. This is particularly important since TNF α is a
major pathological marker in IBD [50], while the serum
level of TNF α correlates with the clinical activity of CD
and UC [51].
The characteristics of the exercise stimulus, such as
frequency, intensity, time (duration) and type (FITT-Cri-
teria) [52], have a direct impact on the release of the
anti-inflammatory cytokines. The IL-6 plasma concen-
tration increases almost exponentially in relation to the
duration of exercise. For instance, 30 min of endurance
training at 75% VO2max increases the IL-6 plasma con-
centration by five times. Further investigations have
shown that the type of exercise as well as the amount of
recruited muscle mass determine the extent of IL-6 re-
lease [53]. PA involving several large muscle groups,
such as brisk walking or rowing, has shown the highest
plasma IL-6 increase [45]. Although other mediators,
like adrenaline, that blunts the appearance of TNF α,
may contribute to the anti-inflammatory effect of exer-
cise, the findings from Pedersen and colleagues
emphasize that muscle derived IL-6 is the true anti-
inflammatory exercise factor [53].
Disease activity
Eight out of the 13 included studies assessed changes in
disease activity by using validated metrics [30, 34, 35,
37–40, 43] (HBI n = 4, CDAI n = 2; RI n = 2, SCCAI n =
1). In three of these studies, positive effects on the dis-
ease activity indices were found. The five remaining
studies found neither positive nor negative effects of the
interventions on clinical disease activity. Given that the
studies did not find any increase of the disease activity,
exercise can be seen as feasible and safe for this popula-
tion. To further investigate potential mechanisms and
effects of exercise on the disease activity, it might be
useful to look into the single disease activity parameters
of the assessment tools, considering a physiological
rationale.
Health benefits of PA interventions in IBD
a) Physical effects
The included interventional studies barely report phys-
ical effects thus estimations of the cardiovascular, mus-
cular, and bony adaptions remain uncertain and had to
be derived from studies conducted in other clinical pop-
ulations [29]. Nevertheless, the few studies that investi-
gated the effect of the interventions on physical
parameters show an increase in VO2max [39], muscle
strength [40, 42] and BMD [33].
An increased risk to develop osteopenia or osteopor-
osis, is very common in IBD. Approximately 40% of all
IBD patients have developed osteoporosis [10–12].
Nonetheless, the causes of low BMD are multifactoral in
IBD patients, an increase in pro-inflammatory cytokines
disturbes the bone remodelling process by increasing
osteoclastic and inhibiting osteoblastic functions [10,
57]. Most IBD patients present a decreased muscle mass
in comparison to their healthy controls [16], which can
be attributed to the catabolic effect of cytokines [58, 59],
physical inactivity [23, 24], malnutrition and malabsorp-
tion [60] as well as the use of corticosteroids [17, 61].
IBD patients also seem to suffer from reduced cardiore-
spiratory fitness, with a direct link to low PA levels [16,
18]. This is of significance, since reduced physical fitness
levels are correlated to increased systemic inflammation
[47].
Muscle strength, BMD as well as VO2max are essential
predictors of all-cause mortality in a wide range of popu-
lations [62], thus, these can be seen as surrogate param-
eters for several health parameters, such as physical
functioning and autonomy.
b) Psychological effects
Although fatigue affects nearly 50% of patients in clinical
remission and over 80% with active disease [65], none of
the included studies assessed it. Fatigue, an intense tired-
ness with reduced energy levels and feelings of exhaus-
tion [63], is considered to be the most burdensome
symptom in IBD patients [14, 64]. As known from re-
search of other chronically ill people, PA can effectively
address the symptoms of fatigue [65–67]. Fatigue con-
tributes to a loss in muscle mass due to the lack of PA
[23, 24, 68] especially in a population with an existing
muscular disadvantaged [16]. Hitherto, the etiology of
fatigue cannot be explained [65], though, an assessment
of Cancer Related Fatigue (CRF) shows, that the amount
of circulating pro-inflammatory blood cytokines are
strongly associated with the severity of CRF [69–71]. Al-
though studies involving IBD patients do not investigate
fatigue, studies with CRF patients seem to include rather
promising information [71], meaning the modes of
action PA exhibits on CRF may be beneficial for IBD
patients [65, 67].
Stress and anxiety are typically perceived by IBD
patients and can trigger relapses [72]. One of the two
studies assessed anxiety showed significant reductions in
both, the State and the Trait sum scores [7]. In two out
of three studies, the aerobic exercise groups showed a
significant reduction in stress [30, 39]. Excercise may be
a useful treatment for anxiety and stress. Nevertheless
the relative paucity of evidence leaves the question open
whether a direct mechanism for exercise to reduce
anxiey exists [73]. Possible explanations of reduced anx-
iety levels after PA interventions can be attributed to im-
proved health-related self-efficacy [74] and perceived
control [75] through fitness gains. Both are known to
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positively influence adherence to treatment and medica-
tion [76]. These potential effects of PA are essential for
all chronically ill patients, and thus for people with IBD.
Having a chronic disease that affects bowel function
can impact many aspects of life beyond the medical
symptoms, e.g. social life and the patients’ HrQoL. The
ultimate target of therapy for IBD is to alter the course
of the disease and thus improve the quality of life. The
HrQoL of IBD patients is determined by the markers of
the disease activity, such as increased clinical activity
markers, number of relapses, working disabilities and
hospitalization [77]. Research shows consistent associa-
tions between moderate PA with increased HrQoL not
only for healthy individuals [78] but also for chronically
ill people [79, 80]. Six of the studies report similar ef-
fects on the general HrQoL as well as on the HrQoL-
subscales for structured PA interventions in IBD [30, 34,
35, 37, 39, 42]. A recent cross-sectional study found that
engaging in higher quantities of walking in a moderate
intensity (equivalent to recommended activity guide-
lines) is independently associated with increased physical
HrQoL in people with IBD [81]. PA may be an efficient
non-pharmacological supportive treatment in IBD, and
will increase patient’s HrQoL, but lack of data from
rigorous, methodologically sound RCTs precludes any
definitive conclusions about its effectiveness.
In summary structured PA interventions may have
the potential to break the cycle of physical inactivity,
muscular deconditioning, poor fitness and decreased
BMD, leading to reduced fatigue and anxiety, which
ultimately improve stress, disease management abil-
ities and HrQoL. Besides these effects it is possible
that regular PA and exercise have a beneficial anti-
inflammatory impact on immunologic biomarkers (e.g.
CRP, TNF α) in IBD. In any event, exercise can
improve the physical and psychological health of the
patients.
Most of the existing studies have significant methodo-
logical limitations. In detail we acknowledge the follow-
ing: As known, the recruitment of patients for exercise
studies via advertisement, e.g., newspaper, radio, flyer or
email, results in an ascertainment bias, i.e. only those
who already have a high motivation to exercise will par-
ticipate. Due to the recruitment pathways it is possible
to only reach certain populations, which can skew the
distribution of socioeconomic and educational variables.
The studies were limited to IBD patients with mild to
moderate disease severity, which narrows the applicabil-
ity of the results. In addition, the initial PA level was not
assessed. Changes in PA levels during the study are a
crucial aspect since they impact the benefits from exer-
cise. None of the studies conducted an a priori power
analysis, thus all studies, except of Sharma et al. [7] and
Cramer et al. [35], had very small sample sizes that lead
to uncertain parameter estimates. Merely one study re-
ported blinding of the control group. Since all studies re-
ported every measured outcome and results do not seem
to support the interventions, a publication bias seems
unlikely, but we acknowledge that the absence of a re-
search librarian during the reviewing process may limit
our results. Because of the limited data available, mecha-
nisms of exercise used for IBD can only be hypothesized
at this time (Fig. 2).
Conclusion
As stated by Pedersen et al., PA ‘...represents a natural,
strong anti-inflammatory and metabolic-improving strat-
egy with minor side effects … [45] p.607]’. The benefits
of structured PA interventions on IBD symptoms have
Fig. 2 Possible clinical, physical and psychological effects of PA in IB
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not been sufficiently investigated up to now [82], even
though they are evident in other chronic diseases [29].
Nevertheless, low to moderate PA seems safe for pa-
tients with mild to moderate IBD. Only two out of 13
studies reported slightly negative effects immediately
after the PA intervention, though they did not persist
[43, 35].
We assume, that the little impact of the interventions
on health parameters might have been caused by the
heterogenous training methods and chosen intensities.
Further research upon the most appropriate type of ex-
ercise is required.
Conclusively we deviate - based on this review and de-
rived from existing evidence of morphologic adaptations
and psychosocial effects of PA in other populations - PA
recommendations for IBD patients along with methodo-
logical recommendations for upcoming studies:
 Type and volume of exercise must be sufficient to
stimulate anti-inflammatory effects. Research has
shown, that the anti-inflammatory output of exercise
depends on the FITT-Criteria [45] as well as the
amount of recruited muscle mass [53]. In order to
assist clinicians to advise patients better and improve
the design of future exercise studies, a representa-
tion of recommended FITT criteria, has been pro-
vided in Table 3.
 The maintenance of an active lifestyle is the main
goal of all exercise interventions. Thus, future
studies need to implement psychological techniques
to enhance motivation, self-regulation and self-
reflection, in order to enable patients implement PA
for their individual disease management [83].
 An agreement in standardized assessment
instruments including the most important health
outcomes in IBD would be necessary for the
quantitative synthesis of future studies [28, 84]. The
interventions as well as outcome assessments should
be multidimensional, i.e. the combination of disease-
specific clinical markers with physiological and psy-
chological parameters.
 Future investigations should assess quality of life as
it is an important aspect of medical decision-making
and a major goal of therapy.
 Because of the cyclical nature of IBD and the
individuality of the disease patterns, it is difficult to
conduct standardized large-scale RCTs. To counter-
act this methodological obstacle the application of
systematic N-of-1-trials can be helpful [85].
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Table 3 Physical activity recommendations for patients with
mild-to-moderate IBD
FITT-Criteria The patient should….
F-requency ...engage in moderate PA at least three times a week, even
better five times a week.
I-ntensity ... choose an activity which increases the energy
expenditure by at least a factor of three or four, as it is the
case for brisk walking. For exercise control via heart rate
(HR), the intensity of the exercise should be between 60 –
80% of the maximum HR. Bear in mind: moderate intensity
is key in order to improve inflammation.
T-ime … exercise for at least 30 minutes per day (more is even
better, if tolerated).
T-ype ... engage in an enjoyable activity, to increase the
probability to maintain this behavior. Exercising in groups
can increase the motivation. A mixture of endurance and
resistance exercise is favorable, because it avoids unilateral
training and emphasizes the use of all big muscle groups.
... increase the amount of leisure time PA. “Walk before you
run”.
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